CA2945528C - Methods and systems for determining autism spectrum disorder risk - Google Patents

Methods and systems for determining autism spectrum disorder risk Download PDF

Info

Publication number
CA2945528C
CA2945528C CA2945528A CA2945528A CA2945528C CA 2945528 C CA2945528 C CA 2945528C CA 2945528 A CA2945528 A CA 2945528A CA 2945528 A CA2945528 A CA 2945528A CA 2945528 C CA2945528 C CA 2945528C
Authority
CA
Canada
Prior art keywords
asd
metabolites
metabolite
level
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2945528A
Other languages
English (en)
French (fr)
Other versions
CA2945528A1 (en
Inventor
Ute GEIGENMULLER
Doris Damian
Maciej PACULA
Mark A. DEPRISTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SynapDx Corp
Original Assignee
SynapDx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/493,141 external-priority patent/US20150294081A1/en
Application filed by SynapDx Corp filed Critical SynapDx Corp
Priority to CA3030255A priority Critical patent/CA3030255C/en
Publication of CA2945528A1 publication Critical patent/CA2945528A1/en
Application granted granted Critical
Publication of CA2945528C publication Critical patent/CA2945528C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ecology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
CA2945528A 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk Active CA2945528C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3030255A CA3030255C (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461978773P 2014-04-11 2014-04-11
US61/978,773 2014-04-11
US201462002169P 2014-05-22 2014-05-22
US62/002,169 2014-05-22
US14/493,141 2014-09-22
US14/493,141 US20150294081A1 (en) 2014-04-11 2014-09-22 Methods and systems for determining autism spectrum disorder risk
US14/633,558 2015-02-27
US14/633,558 US9176113B1 (en) 2014-04-11 2015-02-27 Methods and systems for determining autism spectrum disorder risk
PCT/US2015/025247 WO2015157601A1 (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3030255A Division CA3030255C (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk

Publications (2)

Publication Number Publication Date
CA2945528A1 CA2945528A1 (en) 2015-10-15
CA2945528C true CA2945528C (en) 2019-03-12

Family

ID=54264902

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2945528A Active CA2945528C (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk
CA3030255A Active CA3030255C (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk
CA3157221A Pending CA3157221A1 (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3030255A Active CA3030255C (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk
CA3157221A Pending CA3157221A1 (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk

Country Status (6)

Country Link
US (3) US9176113B1 (enExample)
EP (2) EP3151665B1 (enExample)
JP (5) JP6550124B2 (enExample)
CN (2) CN113009122B (enExample)
CA (3) CA2945528C (enExample)
WO (1) WO2015157601A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016000293A (es) * 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
SG11201705444QA (en) * 2015-01-09 2017-07-28 Global Genomics Group Llc Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
NZ776366A (en) 2015-05-22 2023-02-24 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
US20190178900A1 (en) * 2016-05-13 2019-06-13 Stemina Biomarker Discovery, Inc. Autism subsets
US20200061127A1 (en) * 2016-11-11 2020-02-27 Arizona Board Of Regents On Behalf Of Arizona State University Methods and Compositions for Changing Metabolite Levels in a Subject
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
US12025596B2 (en) 2018-02-19 2024-07-02 The Regents Of The University Of Colorado, A Body Corporate 6-oxo-pipecolic acid quantitation by mass spectrometry
JP2022517161A (ja) * 2018-09-11 2022-03-07 メタボロン，インコーポレイテッド マイクロバイオータ関連代謝物の検出および定量のための質量分析検定法
CN110487922B (zh) * 2018-12-17 2022-09-27 广西中烟工业有限责任公司 一种烟叶中苏糖酸和苏糖酸酯的gc-ms分析方法
WO2020206447A2 (en) * 2019-04-05 2020-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic for maternal risk of having a child with autism spectrum disorder
CA3136301A1 (en) * 2019-04-05 2020-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Metabolites as diagnostics for autism spectrum disorder in children with gastrointestinal symptoms
WO2020242744A1 (en) * 2019-05-31 2020-12-03 Metabolon, Inc. Mass spectrometry assay methods for detection of metabolites
CA3147629A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
CN112180005B (zh) * 2020-09-01 2022-10-04 上海市疾病预防控制中心 一种预测鉴定生物样本中酰基肉碱的方法及其应用
KR20230074216A (ko) * 2020-09-21 2023-05-26 몰레큘러 유 코포레이션 자폐 스펙트럼 장애의 진단 및 치료 방법
CN113539478B (zh) * 2021-06-24 2023-04-07 山西医科大学 基于代谢组学的深静脉血栓形成预测模型的建立方法
CN115938490B (zh) * 2023-03-07 2023-06-06 之江实验室 一种基于图表示学习算法的代谢物鉴定方法、系统和设备
WO2026011154A1 (en) * 2024-07-03 2026-01-08 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic tests for autism, gut dysbiosis, gut disorders, and neurological disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178414A (en) 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Packaging material having excellent seal packaging property
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5686311A (en) 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
US6365593B2 (en) * 2000-04-12 2002-04-02 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
US20040121305A1 (en) 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
EP1587955A4 (en) 2002-12-24 2007-03-14 Biosite Inc DIFFERENTIAL DIAGNOSTIC MARKERS AND METHODS OF USE
US20050101023A1 (en) 2003-03-28 2005-05-12 Rogers James A. Methods for diagnosing urinary tract and prostatic disorders
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
US7604948B2 (en) 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
US20070255113A1 (en) 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
EP2052255A2 (en) 2006-08-18 2009-04-29 Huntington Medical Research Institutes Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
JP5306345B2 (ja) 2007-07-26 2013-10-02 フェノメノーム ディスカバリーズ インク 自閉症スペクトラム障害の診断、リスク評価、及びモニタリングを行うための方法
WO2009151967A1 (en) 2008-05-28 2009-12-17 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
GB0912685D0 (en) * 2009-07-22 2009-08-26 Imp Innovations Ltd Methods
CN102576022B (zh) * 2009-08-14 2016-06-15 加利福尼亚大学董事会 诊断和治疗自闭症的方法
CA2797787C (en) 2010-04-29 2019-07-09 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
AU2013230045A1 (en) * 2012-03-05 2014-09-11 Berg Llc Compositions and methods for diagnosis and treatment of pervasive developmental disorder
JP2015510756A (ja) 2012-03-09 2015-04-13 アンテグラージェン 自閉症のリスクを評価するため遺伝子型決定テスト
US20140045702A1 (en) * 2012-08-13 2014-02-13 Synapdx Corporation Systems and methods for distinguishing between autism spectrum disorders (asd) and non-asd development delay
EP2890808A4 (en) * 2012-08-29 2016-09-28 California Inst Of Techn DIAGNOSIS AND TREATMENT OF AUTISTICAL DISEASES

Also Published As

Publication number Publication date
CN106714556A (zh) 2017-05-24
US20240019417A1 (en) 2024-01-18
CA2945528A1 (en) 2015-10-15
JP2021103177A (ja) 2021-07-15
CA3030255C (en) 2022-07-05
EP3151665B1 (en) 2021-03-10
JP2023178345A (ja) 2023-12-14
WO2015157601A1 (en) 2015-10-15
JP6550124B2 (ja) 2019-07-24
US20160091481A1 (en) 2016-03-31
CA3030255A1 (en) 2015-10-15
EP3151665A4 (en) 2018-04-25
US9176113B1 (en) 2015-11-03
CA3157221A1 (en) 2015-10-15
JP2019200210A (ja) 2019-11-21
EP3954991A3 (en) 2022-05-18
CN113009122A (zh) 2021-06-22
JP2017510821A (ja) 2017-04-13
US20150293072A1 (en) 2015-10-15
CN106714556B (zh) 2021-01-26
EP3151665A1 (en) 2017-04-12
JP2025172836A (ja) 2025-11-26
CN113009122B (zh) 2025-01-17
EP3954991A2 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
US20240019417A1 (en) Methods and Systems for Determining Autism Spectrum Disorder Risk
US20240230622A9 (en) Methods and Systems for Determining Autism Spectrum Disorder Risk
EP2997366B1 (en) Biomarkers related to kidney function and methods using the same
US8653006B2 (en) Metabolite biomarkers for the detection of esophageal cancer using NMR
CA2853202A1 (en) Biomarkers for kidney cancer and methods using the same
JP7179356B2 (ja) 代謝物分析を利用したベーチェット病の診断方法
HK40065445A (en) Methods and systems for determining autism spectrum disorder risk
Barranco-Altirriba et al. Guanine and pregnenolone sulfate are associated with incident type 2 diabetes in two independent populations
HK40051641A (zh) 用於测定自闭症谱系病症风险的方法和系统
HK40051641B (zh) 用於测定自闭症谱系病症风险的方法和系统
CN118883955A (zh) 一种阿尔茨海默症生物标志物及其在早期诊断中的应用
CN117647650A (zh) 预测过敏反应严重程度的生物标志物及其用途和试剂盒
CN120891207A (zh) 用于结核病-冠心病共病诊断的脂质生物标志物及其应用
CN112067807A (zh) 肝癌患者血清中筛选预后相关蛋白的方法及其应用
HK1222905B (en) Biomarkers related to kidney function and methods using the same
HK1218331B (zh) 与肾功能相关的生物标记及其使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161011

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404